However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

Cannabix Technologies Inc. (the "Company" or "Cannabix") developer of marijuana and alcohol breath testing devices is pleased to report that it has made significant updates to its Cannabix Marijuana ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... for the treatment of CF,” said Claire L. Keating, M.D., Co-Director of the Gunnar Esiason Adult Cystic Fibrosis and Lung Program at Columbia ...

If that trend continues, it's unlikely the consumer staples, energy, real estate, healthcare, or materials sectors will beat ...

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC <li /> <str ...

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, ...

Enzon Pharmaceuticals has expanded its Board of Directors to four members and appointed Stephen T. Wills as a new director. Wills brings extensive experience from his roles at various ...

Pets can encounter a multitude of potential toxins every day, but the toxicology experts at Pet Poison Helpline have released their annual list of the Top10 Pet Poisons of 2024 based on actual caller ...

October 29, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the Company’s board of directors has determined that an unsolicited and non ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.